IQVIA has launched a new de-identification platform aimed at real-world genomic research and protecting patient privacy.
The company is pitching its new E360 Genomics offering as a scalable genotypic-phenotypic database that assists researchers working with various genomic and clinical outcome data sets.
The platform allows life science customers to aggregate data to conduct various research projects, including association studies of genomics and observable traits, as well as comparative safety and efficacy trials. It can also securely track burden-of-illness and perform discovery analytics using de-identified data, according to the company.
RELATED: QuintilesIMS no more. Say hello to IQVIA
E360 Genomics replaces sensitive data with symbols that represent critical information, without identifying the patient. By removing identifying and phenotypic information from the patient data—while maintaining links between genomic data and clinical outcomes—IQVIA says it can provide more flexible and less expensive approaches to drug discovery and development work.
Late last year, IQVIA began collaborating with Genomics England on a platform connecting clinical results with de-identified genomics data, to help generate evidence for drug research and personalized medicine. It works alongside a new long-term cancer strategy for the NHS, focused on improving early diagnoses.
The project employs IQVIA’s broader E360 platform to help researchers create custom data sets linking clinical and genomic information, and analyze the relationship between genes and observable traits—beginning with patients with rare diseases and their families, as well as those with common cancers.